Filing Flows › Pacira BioSciences (PCRX) › Q1 2026
Pacira BioSciences (PCRX) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 30, 2026
Pacira BioSciences (PCRX) reported revenue of $177M for the first quarter 2026 (Q1 2026), +5% from a year earlier and -10% from the quarter before. Operating margin was 3.9%, net earnings $2.9M (1.6% of revenue).
Pacira BioSciences, Q1 2026: revenue $177M (+5% year over year), operating margin 3.9%, net earnings $2.9M, operating cash flow $25.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $177M | -10% | +5% |
| Operating profit | $6.9M | +195% | +247% |
| Net earnings | $2.9M | +78% | -39% |
| Operating cash flow | $25.7M | -41% | -28% |
| Free cash flow | $23.0M | -47% | -15% |
What changed
Revenue was $177.4M in Q1 2026, up 5% year over year and down 10% from the previous quarter. EXPAREL was the largest line at 81% of revenue. EXPAREL added $6.7M year over year (up 5%), 80% of the total change. Bupivacaine liposome injectable suspension declined 55%.
Operating profit was $6.9M, a 3.9% margin (up 2.7 points year over year). Of the extra revenue versus Q1 2025, 58% reached operating profit, above the 1% margin then. Total costs grew 2% against revenue growth of 5%. The fastest-growing cost line was Research & development (+11%). Net earnings were $2.9M, down 39% year over year. The effective tax rate was 41.7%.
Operating cash flow was $25.7M (down 28% year over year), 881% of net earnings. Non-cash charges added back $21.3M of depreciation and amortization and $13.5M of share-based compensation. Working capital and other items used $12.1M. Capital expenditures of $2.7M left free cash flow of $23.0M.
Questions
What was Pacira BioSciences' revenue in the first quarter 2026?
Pacira BioSciences (PCRX) reported revenue of $177M for the first quarter 2026 (Q1 2026), +5% from a year earlier and -10% from the quarter before.
Was Pacira BioSciences profitable in the first quarter 2026?
Operating profit was $6.9M (3.9% of revenue) and net earnings $2.9M.
Source: Pacira BioSciences 10-Q on SEC EDGAR.